<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04402632</url>
  </required_header>
  <id_info>
    <org_study_id>MDT19027ONYX</org_study_id>
    <nct_id>NCT04402632</nct_id>
  </id_info>
  <brief_title>Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma</brief_title>
  <acronym>EMBOLISE</acronym>
  <official_title>A Study of the Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System In the Treatment of Subacute and Chronic Subdural HEmatoma (EMBOLISE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Neurovascular Clinical Affairs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Neurovascular Clinical Affairs</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of embolization of the
      middle meningeal artery using the Onyx™ Liquid Embolic System for treatment of symptomatic
      subacute or chronic subdural hematoma
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness: Incidence of hematoma recurrence/progression requiring re-intervention</measure>
    <time_frame>60 days post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness: Rate of successful procedural embolization of the target vessel based on DSA imaging</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness: Change in hematoma thickness based on CT/MRI imaging</measure>
    <time_frame>60 days post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness: Change in Midline shift based on CT/MRI imaging</measure>
    <time_frame>60 days post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness: Change in Markwalder scale Grade 0 (normal) to Grade 4 (comatose)</measure>
    <time_frame>24 hours, 2 weeks, 60 days, and 180 days post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness: Change in Motor strength scale Grade 0 (no movement) to Grade 5 (normal)</measure>
    <time_frame>24 hours, 2 weeks, 60 days, and 180 days post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness: Level of consciousness with Glasgow Coma Scale (GCS) from severe brain injury (0-8), moderate brain injury (9-12) and mild brain injury (13-15)</measure>
    <time_frame>24 hours, 2 weeks, 60 days, and 180 days post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness: Change in the Modified Rankin Scale score (mRS) Grade 0 (no symptoms) to 6 (death)</measure>
    <time_frame>60 days and 180 days post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness: Percentage of patients with favorable functional outcome defined as Modified Rankin Scale of 0 to 3</measure>
    <time_frame>60 days and 180 days post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness: Percentage of patients with good functional outcome defined as Modified Rankin Scale of 0 to 2</measure>
    <time_frame>60 days and 180 days post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness: Quality of life assessed by (EuroQol) EQ-5D scale Grade 0 (worst health) to 100 (best health)</measure>
    <time_frame>60 days and 180 days post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of neurological death</measure>
    <time_frame>60 days and 180 days post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of procedural serious complications</measure>
    <time_frame>30 days post-procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">525</enrollment>
  <condition>Subdural Hematoma</condition>
  <arm_group>
    <arm_group_label>Interventional Cohort: Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interventional Cohort: Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational Cohort: Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational Cohort: Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical Management</intervention_name>
    <description>SDH Evacuation (Control)</description>
    <arm_group_label>Interventional Cohort: Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surgical Management + Treatment</intervention_name>
    <description>SDH Evacuation + Embolization</description>
    <arm_group_label>Interventional Cohort: Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Treatment</intervention_name>
    <description>Observation Only (Control)</description>
    <arm_group_label>Observational Cohort: Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment</intervention_name>
    <description>Embolization</description>
    <arm_group_label>Observational Cohort: Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-randomization mRS ≤3

          -  Confirmed diagnosis of chronic or subacute subdural hematoma

          -  Completed informed consent

        Exclusion Criteria:

          -  Life expectancy &lt;1 year

          -  Unable to complete follow-up

          -  Pregnant, lactating, or has a positive pregnancy test at time of admission

          -  Bilateral subacute or chronic SDH

          -  Previous surgical interventions for subacute or chronic SDH

          -  Unable to undergo MMA embolization prior to surgical treatment

          -  Acute SDH

          -  Potentially dangerous anatomic variations leading to increased procedural risk

          -  Previous coronary stent procedure(s) or heart valve surgery within the past 12 months

          -  Contraindicated for removal from antiplatelet and/or anticoagulant medical therapy for
             at least 60 days post-procedure

          -  Pre-randomized Markwalder assessment ≥ 3

          -  CHADS2 score &gt; 3

          -  Unmanaged, uncontrolled bleeding disorders/blood diathesis

          -  International normalized ratio [INR] ≤1.4

          -  Presumed septic embolus, or suspicion of microbial superinfection

          -  CT or MRI evidence of intra-cranial tumor or mass lesion

          -  Contraindication to angiography

          -  Participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jared Knopman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York-Presbyterian Hospital/Weill Cornell Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jason Davies, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buffalo General Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medtronic Neurovascular Clinical Affairs</last_name>
    <phone>1(949) 837-3700</phone>
    <email>rs.embolisestudy@medtronic.com</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma, Subdural</mesh_term>
    <mesh_term>Hematoma, Subdural, Chronic</mesh_term>
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual participant data will be available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

